Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome

Atherosclerosis

Volumn 177, Issue 2, 2004, Pages 367-373

  Corsetti, James P ^a   Zareba, Wojciech ^a   Moss, Arthur J ^a   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

apoB; Factor analysis; Metabolic syndrome; Risk factors

Indexed keywords

APOLIPOPROTEIN B;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FACTORIAL ANALYSIS; FEMALE; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

APOLIPOPROTEINS B; CORONARY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RISK FACTORS;

EID: 8644271689     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.07.019     Document Type: Article

References (20)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):101-12.
2. A.J. Moss, R.E. Goldstein, and V.J. Marder Thrombogenic factors and recurrent coronary events Circulation 99 1999 2517 2522
3. J.P. Corsetti, W. Zareba, and A.J. Moss Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients Atherosclerosis 171 2003 351 358
4. N. Sattar, L. Gaw, and O. Scherbakova Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study Circulation 108 2003 414 419
5. I.T. Joliffe, and B.J.T. Morgan Principal component analysis and exploratory factor analysis Stat Meth Med Res 1 1992 69 95
6. J. Stevens Applied Multivariate Statistics for the Social Sciences 1986 Lawrence Erlbaum Associates Hillsdale, NJ
7. H. Hauner Insulin resistance and the metabolic syndrome - a challenge of the new millennium Eur J Clin Nutr 56 Suppl. 1 2002 S25 S29
8. C.M. Alexander, P.B. Landsman, and S.M. Teutsch NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older Diabetes 50 2003 1210 1214
9. Y.Y. Fadl, W. Zareba, and A.J. Moss History of hypertension and enhanced thrombogenic activity in postinfarction patients Hypertension 41 2003 943 949
10. A.K. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic HyperapoB: the unappreciated atherogenic dyslipoproteinemia in Type 2 diabetes mellitus Ann Int Med 135 2001 447 459
11. B. Lamarche, A. Tchernof, and S. Moorjani Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men Circulation 95 1997 69 75
12. B. Lamarche, A. Tchernof, and P. Mauriege Fasting insulin and apolipoprotein b levels and low-density lipoprotein particle size as risk factors for ischemic heart disease JAMA 279 1998 1955 1961
13. A.D. Sniderman, A.C. St-Pierre, and B. Cantin Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177
14. P.A. Sakkinen, P. Wahl, and M. Cushman Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome Am J Epidemiol 152 2000 897 907
15. G.Y. Lip, and A. Blann vonWillebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34 1997 255 265
16. D.M. Heywood, M.W. Mansfield, and P.J. Grant Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (Type 2) diabetes mellitus Diabetic Med 13 1996 720 725
17. J.B. Meigs, M.A. Mittleman, and D.M. Nathan Hyperinsulinemia, hyperglycemia, and impaired hemostasis - the framingham offspring study JAMA 283 2000 221 228
18. B.G.S. Seligman, J.L. Gross, and A. Biolo Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia Diabetes Care 23 2000 1395 1400
19. R. von Kanel, R.A. Nelesen, and D.T. Le Decrease in the plasma von Willebrand factor concentration following glucose ingestion: the role of insulin sensitivity Metabolism 50 2001 1452 1456
20. I. Mertens, and L.F. Van Gaal Obesity, haemostasis and the fibrinolytic system Obesity Rev 3 2002 85 101